Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02507375
Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients
Terminated
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT02498275
A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02494596
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 79
- Registration Number
- NCT02491892
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02490475
A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis
Completed
- Conditions
- Renal Tubular Acidosis, Distal, With Hemolytic Anemia
- Interventions
- Other: No intervention
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT02490514
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02488330
- Locations
- 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Completed
- Conditions
- Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT02486952
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Phase 3
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1280
- Registration Number
- NCT02486718
- Locations
- 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷Hôpital Universitaire Dupuytren, Limoges, France
Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1292
- Registration Number
- NCT02485483
© Copyright 2025. All Rights Reserved by MedPath